TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. 더 보기
Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540...
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the...
NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in...
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.3377 | 4.78091493924 | 27.98 | 31.02 | 27.24 | 3404645 | 29.14683917 | CS |
4 | -1.3423 | -4.37801696021 | 30.66 | 33.55 | 27.24 | 2486663 | 29.79490069 | CS |
12 | 6.0577 | 26.043422184 | 23.26 | 36.84 | 22.92 | 3077085 | 30.3385308 | CS |
26 | 7.2777 | 33.0204174229 | 22.04 | 36.84 | 16.8901 | 3277885 | 25.91528425 | CS |
52 | 14.5777 | 98.8989145183 | 14.74 | 36.84 | 12.84 | 3323120 | 21.03687181 | CS |
156 | 14.0477 | 91.9954158481 | 15.27 | 36.84 | 3.48 | 3888751 | 15.1882462 | CS |
260 | 14.7877 | 101.77357192 | 14.53 | 56.74 | 3.48 | 3024097 | 18.01620701 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관